Avadel Pharmaceuticals plc Profit Margin

The latest profit margin for AVDL is -0.11% as of September 2025. That compares with -52.53% in the prior-year period — up 99.8% year over year. That is below the Healthcare sector average of 21.34%. Investors often review this figure alongside Avadel Pharmaceuticals plc's historical trend and sector peers before judging valuation or financial health.

Over the past year, AVDL's profit margin moved from -52.53% to -0.11% — a 99.8% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Avadel Pharmaceuticals plc's valuation or profitability profile.

Against Healthcare companies, AVDL currently prints -0.11% for profit margin, while the sector average sits near 21.34%. That is roughly 100.5% below the sector mean. Large gaps often invite a closer look at Avadel Pharmaceuticals plc's growth, margins, and balance sheet.

Profit Margin shows how effectively Avadel Pharmaceuticals plc converts resources into returns. At -0.11%, AVDL may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -52.53% in the prior-year period — up 99.8% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting AVDL's profit margin (-0.11%), review year-over-year change from -52.53%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.